Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.36 |
| ▸ | PDE4A | P27815 | 6/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.36 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674311 | 0.89 | PDE4B (0.37) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL312942 | 0.88 | ALDH1A1 (0.35) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL7996053 | 0.88 | KDM4E (0.36) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL8003756 | 0.87 | KDM4E (0.36) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL10250159 | 0.86 | PTGES (0.37) | PTGES | |
| SCHEMBL313767 | 0.84 | MAPT (0.39) | MAPTMEN1ALDH1A1POLBGAA | |
| SCHEMBL315199 | 0.83 | ALDH1A1 (0.37) | MAPTMEN1ALDH1A1POLBGAA | |
| SCHEMBL3797063 | 0.81 | GAA (0.37) | PDE4BPDE4APDE4CPDE4DPDE11A | |
| SCHEMBL995496 | 0.81 | ALDH1A1 (0.35) | PDE4BPDE4APDE4CPDE4DMAPT | |
| SCHEMBL314535 | 0.80 | ALDH1A1 (0.35) | MAPTMEN1ALDH1A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417134-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2461811-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9284307-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| EP-2250174-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| EP-2250174-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8377962-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2461811-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2417134-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20100196321-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196321-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196321-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | US | disclosed |
| WO-2010088394-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009099596-A2 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARAMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | PDE4B 4264/4885PDE4A 4231/4885PDE4C 4169/4885 |
| US-20100016578-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | PDE4B 4264/4885PDE4A 4231/4885PDE4C 4169/4885 |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | PDE4B 4014/4885PDE4A 4127/4885PDE4C 4147/4885 |
| US-20100196321-A1 | COMPOUNDS | HAVCR2, ACE, ACE2 | PDE4B 1867/4885PDE4A 2279/4885PDE4C 2327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.